We could not find any results for:
Make sure your spelling is correct or try broadening your search.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angio... KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. Show more
– Delays in treating attacks lead to increased anxiety, quality of life issues, higher frequency of returning attacks, and suboptimal clinical outcomes in both on-demand and prophylaxis patients...
– Full EAMS designation would allow treatment of patients with sebetralstat prior to receiving a Marketing Authorization from UK – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage...
false000134891100013489112024-03-112024-03-11 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...
--04-30falseQ300013489110001348911us-gaap:CommonStockMember2023-08-012023-10-310001348911us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-01-310001348911us-gaap:Accumula...
- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors...
false 0001348911 0001348911 2024-03-06 2024-03-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT...
– Planned transition reflects evolution to commercial company with sebetralstat for HAE – – NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 – KalVista Pharmaceuticals...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.44 | -3.57723577236 | 12.3 | 12.7 | 10.7 | 370305 | 11.37549665 | CS |
4 | -1.72 | -12.6656848306 | 13.58 | 14.62 | 10.7 | 554244 | 12.95254116 | CS |
12 | -0.27 | -2.22588623248 | 12.13 | 16.88 | 10.7 | 804123 | 13.88814107 | CS |
26 | 2.02 | 20.5284552846 | 9.84 | 16.88 | 7.21 | 553820 | 12.42859241 | CS |
52 | 5.23 | 78.8838612368 | 6.63 | 16.88 | 6.6 | 385190 | 11.66639919 | CS |
156 | -16.15 | -57.6579792931 | 28.01 | 30.7 | 4.12 | 313530 | 12.60365851 | CS |
260 | -16.4 | -58.0325548478 | 28.26 | 45 | 4.12 | 281542 | 16.70863239 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions